Home / Partnerships


Partnering and collaborations are essential parts of PEPTONIC medical’s business model. We are dependent on our partners for advancing the development of our pipeline products according to our plans and expectations. Hence, we put a lot of emphasis on partnering activities and on managing our partnerships and alliances.


PEPTONIC medical’s most advanced program – VagiVital™ – for the treatment of vaginal atrophy – is in commercialization phase. This a hormone free medical device product with no active substances. We are seeking partners for registration, commercial launch and distribution in all geographies.

In addition to vaginal atrophy, PEPTONIC medical owns patents relating to the use of oxytocin for a number of medical indications. Please, contact us for more information about these opportunities.


For information about partnering and partnering opportunities, please contact;

Erik Sundquist

Erik Sundquist

Chief Executive Officer
+46 722 499 043


Recent Comments

    All press releases on Spotlightstockmarket.com

    All published press releases from PEPTONIC medical is available on spotlightstockmarket.com.

    About us

    PEPTONIC Medical is an innovative Swedish pharmaceutical company developing and commercializing safe and effective products for the treatment of menopausal symptoms, such as vaginal atrophy. VagiVital® is a registered trademark of PEPTONIC Medical. The product is being commercialised for the non-prescription use for the treatment of vaginal atrophy.

    The Company was founded in 2009 and its first candidate drug product is Vagitocin® – an estrogen-free oxytocin based product for the treatment of vaginal atrophy in clinical development phase 2.

    Oxytocin has a long history of safe and effective medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women.